ADAR1 Capital Management »

Bridgebio Pharma shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Bridgebio Pharma (BBIO) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Bridgebio Pharma

Tip: Access up to 7 years of quarterly data

All positions including Bridgebio Pharma held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Bridgebio Pharma by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $17M 551k 30.92
2023-12-31 $7.5M 185k 40.37

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Bridgebio Pharma

Kohlberg Kravis Roberts & Co
Viking Global Investors
Vanguard Group
BlackRock
BlackRock
Aisling Capital Management
State Street Corporation
Susquehanna International
Henderson Group
Laurion Capital Management
Frazier Life Sciences Management
Geode Capital Management
Citadel Advisors
Pictet Asset Management Holding SA
Jane Street

View all funds holding Bridgebio Pharma